Use of exogenous hormones by women and lung cancer

evidence from the Royal College of General Practitioners' Oral Contraception Study

Alison Margaret Elliott, Philip Christopher Hannaford

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: The objective of this study was to assess the risk of lung cancer among women who have used oral contraception or hormone replacement therapy (HRT), especially those exposed to both classes of exogenous hormones.

Design: This study is a nested case-control one using prospectively collected data from the Royal College of General Practitioners' Oral Contraception Study (OCS). The 162 case patients were women with a diagnosis of lung cancer recorded on the OCS database by August 2004. Each case patient was matched with 3 control Subjects who were free of the disease at the time of the case patient's diagnosis, of similar age and with similar length Of follow-up in the OCS.

Results: Compared with never use, current use of oral contraception was associated with a statistically nonsignificant reduced risk of lung cancer, with an adjusted odds ratio (OR) of 0.47 and a 95% confidence interval (CI) of 0.08-2.95 (OR=0.86 and 95% CI=0.50-1.48 for former use; OR=0.84 and 95% CI=0.49-1.43 for ever use). Similar comparisons for HRT were current use (OR=1.21, 95% CI=0.23-6.37), former use (OR=0.62, 95% CI=0.23-1.68) and ever use (OR=0.71, 95% CI=0.28-1.78). The OR among women who had used both classes of hormones was 0.53 (95% CI=0.16-1.72), as compared with those who had used neither.

Conclusions: Our results are compatible with findings from other studies that suggest that oral contraceptives may reduce the risk of lung cancer. Evidence for a beneficial effect of HRT is less convincing. Further study is needed to determine how long any benefit lasts and whether it is stronger in women exposed to both classes of exogenous hormones. The small number of events occurring in this very large cohort, however, shows that any public health benefit is likely to be marginal. (c) 2006 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)331-335
Number of pages4
JournalContraception
Volume73
Issue number4
Early online date15 Dec 2005
DOIs
Publication statusPublished - Apr 2006

Keywords

  • exogenous hormones
  • hormone replacement therapy
  • lung cancer
  • oral contraception
  • women
  • replacement therapy
  • cigarette-smoking
  • histologic type
  • sex-differences
  • risk
  • gender
  • mortality
  • smokers

Cite this

Use of exogenous hormones by women and lung cancer : evidence from the Royal College of General Practitioners' Oral Contraception Study . / Elliott, Alison Margaret; Hannaford, Philip Christopher.

In: Contraception, Vol. 73, No. 4, 04.2006, p. 331-335.

Research output: Contribution to journalArticle

@article{78d746f7838b45f493915f40c00d6ab6,
title = "Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study",
abstract = "Objective: The objective of this study was to assess the risk of lung cancer among women who have used oral contraception or hormone replacement therapy (HRT), especially those exposed to both classes of exogenous hormones.Design: This study is a nested case-control one using prospectively collected data from the Royal College of General Practitioners' Oral Contraception Study (OCS). The 162 case patients were women with a diagnosis of lung cancer recorded on the OCS database by August 2004. Each case patient was matched with 3 control Subjects who were free of the disease at the time of the case patient's diagnosis, of similar age and with similar length Of follow-up in the OCS.Results: Compared with never use, current use of oral contraception was associated with a statistically nonsignificant reduced risk of lung cancer, with an adjusted odds ratio (OR) of 0.47 and a 95{\%} confidence interval (CI) of 0.08-2.95 (OR=0.86 and 95{\%} CI=0.50-1.48 for former use; OR=0.84 and 95{\%} CI=0.49-1.43 for ever use). Similar comparisons for HRT were current use (OR=1.21, 95{\%} CI=0.23-6.37), former use (OR=0.62, 95{\%} CI=0.23-1.68) and ever use (OR=0.71, 95{\%} CI=0.28-1.78). The OR among women who had used both classes of hormones was 0.53 (95{\%} CI=0.16-1.72), as compared with those who had used neither.Conclusions: Our results are compatible with findings from other studies that suggest that oral contraceptives may reduce the risk of lung cancer. Evidence for a beneficial effect of HRT is less convincing. Further study is needed to determine how long any benefit lasts and whether it is stronger in women exposed to both classes of exogenous hormones. The small number of events occurring in this very large cohort, however, shows that any public health benefit is likely to be marginal. (c) 2006 Elsevier Inc. All rights reserved.",
keywords = "exogenous hormones, hormone replacement therapy, lung cancer, oral contraception, women, replacement therapy, cigarette-smoking, histologic type, sex-differences, risk, gender, mortality, smokers",
author = "Elliott, {Alison Margaret} and Hannaford, {Philip Christopher}",
year = "2006",
month = "4",
doi = "10.1016/j.contraception.2005.10.003",
language = "English",
volume = "73",
pages = "331--335",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Use of exogenous hormones by women and lung cancer

T2 - evidence from the Royal College of General Practitioners' Oral Contraception Study

AU - Elliott, Alison Margaret

AU - Hannaford, Philip Christopher

PY - 2006/4

Y1 - 2006/4

N2 - Objective: The objective of this study was to assess the risk of lung cancer among women who have used oral contraception or hormone replacement therapy (HRT), especially those exposed to both classes of exogenous hormones.Design: This study is a nested case-control one using prospectively collected data from the Royal College of General Practitioners' Oral Contraception Study (OCS). The 162 case patients were women with a diagnosis of lung cancer recorded on the OCS database by August 2004. Each case patient was matched with 3 control Subjects who were free of the disease at the time of the case patient's diagnosis, of similar age and with similar length Of follow-up in the OCS.Results: Compared with never use, current use of oral contraception was associated with a statistically nonsignificant reduced risk of lung cancer, with an adjusted odds ratio (OR) of 0.47 and a 95% confidence interval (CI) of 0.08-2.95 (OR=0.86 and 95% CI=0.50-1.48 for former use; OR=0.84 and 95% CI=0.49-1.43 for ever use). Similar comparisons for HRT were current use (OR=1.21, 95% CI=0.23-6.37), former use (OR=0.62, 95% CI=0.23-1.68) and ever use (OR=0.71, 95% CI=0.28-1.78). The OR among women who had used both classes of hormones was 0.53 (95% CI=0.16-1.72), as compared with those who had used neither.Conclusions: Our results are compatible with findings from other studies that suggest that oral contraceptives may reduce the risk of lung cancer. Evidence for a beneficial effect of HRT is less convincing. Further study is needed to determine how long any benefit lasts and whether it is stronger in women exposed to both classes of exogenous hormones. The small number of events occurring in this very large cohort, however, shows that any public health benefit is likely to be marginal. (c) 2006 Elsevier Inc. All rights reserved.

AB - Objective: The objective of this study was to assess the risk of lung cancer among women who have used oral contraception or hormone replacement therapy (HRT), especially those exposed to both classes of exogenous hormones.Design: This study is a nested case-control one using prospectively collected data from the Royal College of General Practitioners' Oral Contraception Study (OCS). The 162 case patients were women with a diagnosis of lung cancer recorded on the OCS database by August 2004. Each case patient was matched with 3 control Subjects who were free of the disease at the time of the case patient's diagnosis, of similar age and with similar length Of follow-up in the OCS.Results: Compared with never use, current use of oral contraception was associated with a statistically nonsignificant reduced risk of lung cancer, with an adjusted odds ratio (OR) of 0.47 and a 95% confidence interval (CI) of 0.08-2.95 (OR=0.86 and 95% CI=0.50-1.48 for former use; OR=0.84 and 95% CI=0.49-1.43 for ever use). Similar comparisons for HRT were current use (OR=1.21, 95% CI=0.23-6.37), former use (OR=0.62, 95% CI=0.23-1.68) and ever use (OR=0.71, 95% CI=0.28-1.78). The OR among women who had used both classes of hormones was 0.53 (95% CI=0.16-1.72), as compared with those who had used neither.Conclusions: Our results are compatible with findings from other studies that suggest that oral contraceptives may reduce the risk of lung cancer. Evidence for a beneficial effect of HRT is less convincing. Further study is needed to determine how long any benefit lasts and whether it is stronger in women exposed to both classes of exogenous hormones. The small number of events occurring in this very large cohort, however, shows that any public health benefit is likely to be marginal. (c) 2006 Elsevier Inc. All rights reserved.

KW - exogenous hormones

KW - hormone replacement therapy

KW - lung cancer

KW - oral contraception

KW - women

KW - replacement therapy

KW - cigarette-smoking

KW - histologic type

KW - sex-differences

KW - risk

KW - gender

KW - mortality

KW - smokers

U2 - 10.1016/j.contraception.2005.10.003

DO - 10.1016/j.contraception.2005.10.003

M3 - Article

VL - 73

SP - 331

EP - 335

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -